Systemic Leakage and Side Effects of Tumor Necrosis Factor α Administered Via Isolated Limb Perfusion Can Be Manipulated by Flow Rate Adjustment

Archives of Surgery

Volumn 130, Issue 10, 1995, Pages 1079-1084

  Sorkin, Patrik ^a   Abu Abid, Subhi ^b   Lev, Dina ^b   Gutman, Mordechai ^b   Aderka, Dan ^b   Halpern, Pinhas ^a   Setton, Aric ^a   Kudlik, Nahman ^b   Bar, Jack ^c   Rudich, Valery ^a   Meller, Isaak ^d   Klausner, Joseph M ^b  

^a Departments of Intensive Care and Anesthesiology ^*  (Israel)

^b Departments of Surgery B and C   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PROTHROMBIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON DIOXIDE TENSION; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG TOLERANCE; FLOWMETER; HEART OUTPUT; HUMAN; HYPOCHOLESTEROLEMIA; HYPOTENSION; LIMB PERFUSION; OXYGEN TENSION; PH; PRIORITY JOURNAL; REGIONAL PERFUSION; SEPSIS; SOFT TISSUE SARCOMA; STATISTICAL ANALYSIS; SYSTEMIC VASCULAR RESISTANCE; TACHYCARDIA; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ARM; BLOOD CELL COUNT; CHOLESTEROL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMODYNAMICS; HUMAN; LEG; LIVER FUNCTION TESTS; MALE; MELANOMA; MELPHALAN; METABOLISM; MIDDLE AGE; PERFUSION, REGIONAL; RECOMBINANT PROTEINS; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR NECROSIS FACTOR;

EID: 0029098875     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.1995.01430100057012     Document Type: Article

References (33)

1. Haranaka K, Satomi N, Sukari A. Antitumor activity of murine tumor necrosis factor against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer. 1984;34:263-267.
2. Asher AL, Mule JY, Reichert CM, Shilon E, Rosenberg SA. Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987;138:963-974.
3. Balkwill F, Lee A, Aldam G, et al. Human tumor xenografts treated with human TNF alone or in combination with IF. Cancer Res. 1986;46:3990-3993.
4. Spriggs DR, Sherman KL, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-h intravenous infusion: a phase I and pharmacologic study. J Natl Cancer Inst. 1988;80:1039-1044.
5. Creaven PJ, Plager JE, Dupere S, et al. Phase I trial of recombinant human necrosis factor. Cancer Chemother Pharmacol. 1987;20:137-144.
6. lick MB, Sherwin SA, Rosenblum M, et al. A phase I trial of recombinant human necrosis factor in cancer patients. Cancer Res. 1987;47:2986-2989.
7. Chapman PB, Laster TY, Casper ES, et al. Clinical pharmacology of recombinant tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987;5:1942-1951.
8. Feinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenously administered recombinant tumor necrosis factor alpha in cancer patients. J Clin Oncol. 1988:6:1328-1334.
9. Dematri GD, Spriggs DR, Sherman UL, et al. A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo. J Clin Oncol. 1989;7:1545-1553.
10. Tracey K, Beutler B, Lowry S, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470-474.
11. Tracey KJ, Beutler B, Lawry SF, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 1987;164:415-421.
12. Lienard O, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52-60.
13. Rosenberg SA, Suit HD, Barker LH. Sarcomas of soft tissue. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia, Pa: JB Lippincott; 1993:1436-1488.
14. Eggermont AMM, Lienard D, Schraffordt KH, Rosekaimer F, Lejeune FJ. In: Fiers W, Buurman WA, eds. Treatment of Irresectable Soft Tissue Sarcomas of the Limbs by Isolation Perfusion With High Dose TNF-α in Combination With Interferon and Melphalan. New York, NY: S Karger AG; 1993:239-243.
15. Lienard D, Lejeune F, Evvalenko I. In transit metastases of malignant melanoma treated by high dose r-TNFα in combination with interferon gamma and melphalan in isolation perfusion. World J Surg. 1992;16:234-240.
16. Koops HS, Kroon BBR, Lejeune FJ. Isolated regional perfusion in the treatment of local recurrence, satellites and in transit metastases of extremity melanoma. In: Ramke P, ed. Therapy of Advanced Melanoma. New York, NY: S Karger AG; 1990:67-78.
17. Fraker DL, Alexander HR. The use of tumor necrosis factor in isolated limb perfusions for melanoma and sarcoma. Principals Pract Oncol. 1993;7:5-12.
18. Krementz ET, Cartger RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs in regional perfusion. Ann Surg. 1977;185:555-564.
19. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor alpha in cancer patients. J Clin Oncol. 1988;6:1328-1334.
20. Krementz ET, Ryan RF, Carter RD, Sutherland CM, Reed RJ. Hyperthermic regional perfusion for melanoma of the limbs. In: Balch CM, Milton GW, eds. Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. Philadelphia, Pa: JB Lippincott; 1985:171-195.
21. Beutler B, Cerami A. Tumor necrosis, cachexia shock and inflammation: a common mediator. Ann Rev Biochem. 1988;57:515-518.
22. Beutler B, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution and metabolic fate in vivo. J Immunol. 1985;135:3972-3977.
23. Greenberg S, Xie J, Wang Y, et al. Tumor necrosis factor alpha inhibits endothelium-dependent relaxation. J Appl Physiol. 1993;74:2394-2403.
24. Koide M, Kwahara Y, Tsuda T, Yokoyama N. Cytokine-induced expression of an inducible type of nitric oxide synthase gene in cultured vascular smooth muscle cells. FEBS Lett. 1993;318:213-217.
25. Aderka D, Maor Y, Novick D, et al. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-α or -β. Blood. 1993;81:2076-2084.
26. Hesse DG, Tracey KY, Fong Y. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 1988;166:147-153.
27. Tracy KY, Lowry SF, Cerami A. Cachectin/TNF in septic shock and septic adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138:1377-1379.
28. Ulich TR, Del Castillo J, Keys M. Kinetics and mechanisms of recombinant human interleukin I and tumor necrosis factor α—induced changes in circulatory numbers of neutrophils and lymphocytes. J Immunol. 1987;139:3406-3415.
29. Smith CW, Martin SD, Rothelin R. Cooperative interaction of LFA-1 and MAC-1 with intracellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest. 1989;83:2008-2017.
30. Kishimoto TK, Jutila MA, Berg EL. Neutrophil MAC-1 and MEL-14 adhesion protein inversely regulated by chemotactic factors. Science. 1989;245:1238-1242.
31. Weisensee D, Bereiler HJ, Schoeppe W, Low FI. Effects of cytokines on the contractility of cultured cardiac myocytes. Int J Immunopharmacol. 1993;15: 581-587.
32. del Giglio A, Zukiwski AA, Ali MK, Mavligit GM. Severe symptomatic dose-limiting hypophosphatemia induced by hepatic arterial infusion of recombinant tumor necrosis factor in patients with liver metastasis. Cancer. 1991;67: 2459-2461.
33. Salomon GD, Kasid A, Cromack DT, et al. The local effects of cachectin/tumor necrosis factor on wound healing. Ann Surg. 1991;214:175-180.